Theracryf Plc
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and n… Read more
Theracryf Plc (TCF) - Total Assets
Latest total assets as of September 2025: GBX6.62 Million GBX
Based on the latest financial reports, Theracryf Plc (TCF) holds total assets worth GBX6.62 Million GBX as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Theracryf Plc - Total Assets Trend (2017–2025)
This chart illustrates how Theracryf Plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Theracryf Plc - Asset Composition Analysis
Current Asset Composition (March 2025)
Theracryf Plc's total assets of GBX6.62 Million consist of 67.8% current assets and 32.2% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 27.6% |
| Accounts Receivable | GBX404.00K | 5.3% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX2.46 Million | 32.2% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Theracryf Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theracryf Plc's current assets represent 67.8% of total assets in 2025, a decrease from 97.1% in 2017.
- Cash Position: Cash and equivalents constituted 27.6% of total assets in 2025, down from 81.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 32.2% of total assets.
Theracryf Plc Competitors by Total Assets
Key competitors of Theracryf Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Theracryf Plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Theracryf Plc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Theracryf Plc is currently not profitable relative to its asset base.
Theracryf Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.29 | 4.36 | 6.71 |
| Quick Ratio | 2.29 | 4.36 | 6.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX2.35 Million | GBX 1.57 Million | GBX 2.48 Million |
Theracryf Plc - Advanced Valuation Insights
This section examines the relationship between Theracryf Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 149.2% |
| Total Assets | GBX7.63 Million |
| Market Capitalization | $536.01 USD |
Valuation Analysis
Below Book Valuation: The market values Theracryf Plc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Theracryf Plc's assets grew by 149.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Theracryf Plc (2017–2025)
The table below shows the annual total assets of Theracryf Plc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | GBX7.63 Million | +149.18% |
| 2024-03-31 | GBX3.06 Million | -50.40% |
| 2023-03-31 | GBX6.17 Million | -35.94% |
| 2022-03-31 | GBX9.64 Million | -22.39% |
| 2021-03-31 | GBX12.42 Million | +155.67% |
| 2020-03-31 | GBX4.86 Million | +75.72% |
| 2019-03-31 | GBX2.76 Million | -35.12% |
| 2018-03-31 | GBX4.26 Million | -10.16% |
| 2017-03-31 | GBX4.74 Million | -- |